Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

Researchers with Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real ...

More patients enrolled in clinical trials should help refine both opsin delivery and the ability to improve light sensitivity ...

Errors of refraction and strabismic amblyopia were the most common causes of low vision. Retinal diseases most frequently caused severe vision loss. Income and insurance type were not linked to ...